Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor

Blood Cancer Journal, Published online: 04 January 2023; doi:10.1038/s41408-022-00780-9Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor

Source: Blood Cancer Journal - January 4, 2023 Category: Hematology Authors: Naseema Gangat Kebede H. Begna Aref Al-Kali William Hogan Mark Litzow Animesh Pardanani Ayalew Tefferi Source Type: research